Mirum Pharmaceuticals’ LIVMARLI Receives Reimbursement Recommendation By Canada’s CADTH For Patients With Cholestatic Pruritus In Alagille Syndrome
- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder- LIVMARLI is the first and only approved medication to